{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Axogen, Inc. Hits New 52-Week High of $22.95, Surges 217.86%
Axogen, Inc. has achieved a new 52-week high of USD 22.95, reflecting a significant year-over-year performance increase. With a market capitalization of USD 738 million, the company operates in a competitive sector but is currently not generating profits and does not offer dividends, focusing on growth instead.
Axogen, Inc. Experiences Evaluation Revision Amidst Shifting Market Dynamics and Performance Indicators
Axogen, Inc. has recently revised its evaluation amid changing market dynamics. The stock is priced at $17.16, with a notable one-year return of 25.53%, outperforming the S&P 500. Various technical indicators show mixed signals, reflecting the company's resilience and performance trends in the competitive landscape.
Is Axogen, Inc. technically bullish or bearish?
As of October 3, 2025, Axogen, Inc. has a bullish trend with strong indicators like a bullish MACD and moving averages, though the weekly RSI shows short-term weakness, and while it has outperformed the S&P 500 recently, it has lagged in the longer term.
Axogen Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
Axogen, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock has outperformed the S&P 500 over the past year and shows positive short-term trends. Despite mixed signals from other indicators, overall bullish trends suggest strong investor interest in the company.
Is Axogen, Inc. technically bullish or bearish?
As of October 3, 2025, Axogen, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed monthly signals, and has outperformed the S&P 500 over the past year with a 34.03% return.
Is Axogen, Inc. technically bullish or bearish?
As of October 3, 2025, Axogen, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed monthly signals, and has outperformed the S&P 500 over the past year.
Axogen, Inc. Experiences Evaluation Revision Amid Mixed Performance Indicators and Market Dynamics
Axogen, Inc. has recently revised its evaluation amid fluctuating market conditions, with its stock priced at $17.20. The company has shown significant volatility over the past year, with mixed technical indicators and performance that has outpaced the S&P 500 in shorter time frames, but lagged over longer periods.
Is Axogen, Inc. technically bullish or bearish?
As of September 11, 2025, Axogen, Inc. shows a mildly bullish trend with positive signals from Bollinger Bands and KST, despite some bearish indicators, having outperformed the S&P 500 recently but underperformed over longer periods.
Is Axogen, Inc. technically bullish or bearish?
As of June 9, 2025, Axogen, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD, moving averages, and Bollinger Bands, despite a bullish weekly RSI.
Who are in the management team of Axogen, Inc.?
As of March 2022, the management team of Axogen, Inc. includes Ms. Karen Zaderej as Chairman, President, and CEO, with Ms. Amy Wendell as Lead Independent Director and directors Mr. Gregory Freitag, Mr. Paul Thomas, Mr. Quentin Blackford, and Dr. Mark Gold.
What does Axogen, Inc. do?
Axogen, Inc. provides surgical solutions for peripheral nerve injuries and operates in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $49 million and a net loss of $4 million, with a market cap of $434.03 million.
How big is Axogen, Inc.?
As of Jun 18, Axogen, Inc. has a market capitalization of 434.03 million and reported net sales of 194.52 million with a net profit of -7.16 million over the latest four quarters. Shareholder's funds are at 103.91 million, and total assets are 203.73 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
